Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis.

Stefanos BonovasGeorgios K NikolopoulosTheodore LytrasGionata FiorinoLaurent Peyrin-BirouletSilvio Danese

Published in: British journal of clinical pharmacology (2017)

Budesonide MMX is associated with fewer corticosteroid-related AEs than its comparator steroid treatments for adult IBD patients. Further high-quality research is warranted to illuminate the steroid drugs' comparative safety profiles.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
young adults